Analysts reality-check Dupixent’s ‘megabrand’ ambition
Analysts say the drug’s road to megabrand status may depend on uptake in some rather obscure disease areas.
Analysts say the drug’s road to megabrand status may depend on uptake in some rather obscure disease areas.
Several candidates relegated to the R&D graveyard re-emerged from their tombs this year and now headline the pharma developmental slate for 2020.
Analysts from Jefferies predicted up to $2 billion in peak sales if Amarin’s seven-year trial data is positive.
Two touted products in the pipeline reflect three of medical marketing’s most profound modern-era challenges.
Sun Pharma’s branded prostate cancer treatment Yonsa just received FDA approval.
Novo Nordisk diabetes pill delivers in late-stage trial; Gilead partners with Sangamo on engineered cell therapies; Study finds antidepressants work, though with varying results.
AbbVie reports successful elagolix trial; White House touts short-term insurance plans; Mayo Clinic chief to retire.
Clayman says the company’s next 18 months are all about Zilretta, with further pipeline construction next up.
Biogen, UCB reportedly showing interest in Acorda acquisition; Kite Pharma and Pfizer to develop combo lymphoma therapy; hospitals to form generics nonprofit
Takeda announces deals worth more than $1 billion; biotech and pharma investments reached $10.5 billion in 2017; prescriptions for nerve pain on the rise